Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6516020 | 0.86 | TNFRSF1A (0.44) | TNFRSF1A | |
| SCHEMBL6040637 | 0.82 | CA2 (0.41) | CA2CA9MAPTKMT2AMEN1 | |
| SCHEMBL5559525 | 0.82 | HPGD (0.43) | CA2MAPTKMT2AMEN1TSHR | |
| SCHEMBL6040478 | 0.80 | CA2 (0.40) | CA2CA9 | |
| SCHEMBL6040594 | 0.78 | TNFRSF1A (0.39) | MAPTKMT2AMEN1TNFRSF1ARXFP1 | |
| SCHEMBL6040746 | 0.75 | TNFRSF1A (0.39) | MAPTTNFRSF1ARXFP1 | |
| SCHEMBL5564344 | 0.72 | NPC1 (0.45) | CA2KMT2AMEN1TSHRPOLB | |
| SCHEMBL5564202 | 0.71 | HPGD (0.49) | CA2CA9MAPTKMT2AMEN1 | |
| SCHEMBL5560084 | 0.71 | HPGD (0.49) | CA2CA9MAPTKMT2AMEN1 | |
| SCHEMBL6040578 | 0.69 | TNFRSF1A (0.47) | CA2CA9MAPTTNFRSF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050049236-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | CRABTREE ACQUISITION CO, LLC | 2005-03-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049236-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | STS, HPSE, SULT1E1 | CA2 899/4885CA9 1619/4885MAPT 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.